Plus   Neg

Nordstrom Board Rejects Family Proposal To Go Private

Nordstrom Inc. (JWN) Monday said a special committee of the Board of Directors has rejected a proposal to take the company private after considering it to be insufficient.

Nordstrom said a group consisting of members of the Nordstrom family, including the company Co-Presidents Blake Nordstrom, Peter Nordstrom, and Erik Nordstrom, President of Stores James Nordstrom, Chairman Emeritus Bruce Nordstrom, and Anne Gittinger, notified the company that it intends to submit a proposal to purchase all shares of the company not already owned by the Group, and approximately 21% of the shares owned by the Nordstrom family members in the Group for $50.00 per share in cash, the company said in a statement.

The Special Committee reviewed the Group's proposal in consultation with its financial advisor and legal counsel and has determined that the price proposed is inadequate.

The Special Committee has directed its advisors and management not to provide further due diligence information to the Group. Furthermore, unless the Group can promptly and substantially improve the price it is proposing to pay for the Company, the Special Committee intends to terminate discussions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT